Nurix Therapeutics, Inc. 4

On 2026-07-02, Chief Legal Officer Christine Ring of Nurix Therapeutics, Inc. exercised options for 11,008 shares of common stock and sold all 11,008 shares at an average price of about $23.56 under a Rule 10b5-1 plan.

On July 2, 2026, Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring exercised two tranches of employee stock options for a total of 11,008 shares of common stock (5,221 shares at an exercise price of $1.86 and 5,787 shares at $8.72) and immediately sold all 11,008 shares in an open‑market transaction under a pre‑established Rule 10b5‑1 trading plan at a weighted average price of $23.5616 per share, for proceeds of approximately $259,400. The option exercises themselves did not generate cash proceeds but converted derivative holdings into common stock, which was then sold, and following these transactions Ring reported direct ownership of 128,611 shares of Nurix common stock. The exercised option grants were previously scheduled awards, with one option fully vested by August 9, 2023, and the other vesting monthly through February 13, 2027, indicating these transactions are part of ongoing equity compensation and liquidity management rather than a new discretionary purchase or sale program.

Filing Facts

CIK

1549595

Ticker

NRIX

Form

4

Source Type

sec

Accession

0001817199-26-000024

Alert Tier

6